本帖最后由 老马 于 2012-1-13 21:20 编辑 3 E" x. ~6 `( n- U
+ j2 R, H3 P1 j0 L/ t* n ^爱必妥和阿瓦斯丁的比较" }3 r: `2 l* l* p
9 E7 o# G% L6 U) \3 W* @" H2 f( J2 _
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
% ^) Q& X8 A" D- E0 G6 \+ v
" I5 E. Q) u+ x8 y9 b
; O# R j1 n% Z" N. W o
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/) x0 x- }9 O d/ { X. Y" l
==================================================
& z1 L7 Y( W" W Z! dOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)7 j3 X" x( K7 p2 H* ?
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 A7 S1 b& K' yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
6 s3 G6 T' G% { f; Q$ ^8 m+ A
|